In results from a MACS study published online August 27, 2013 by the American Society of Microbiology, some people living with HIV face a 20-times higher risk for the fungal disease Cryptococcal neoformans, or “crypto”. This is due to the presence of a gene that expresses…Read More

In an article published in the Journal of Neurovirology (June 2013), results from a small study suggest that physical exercise may reduce neuro-cognitive impairment and improve working memory as well as speed of processing information in HIV-positive people. From 2007-2011, the small study included 83 people…Read More

In an article published online ahead of print in Clinical Infectious Diseases, results from the large COHERE study show that HIV-positive people with 500-750 CD4s have a higher rate of AIDS-defining illnesses (ADI), compared to those with CD4s above 750 cells. Although the comparison is statistically…Read More

Whether you’re HIV-positive or HIV-negative, we’re all affected by HIV. HIV stigma can discourage people from getting tested for HIV, just as it can make others fear disclosing their status to friends and loved ones. Positively Aware, the HIV magazine published by Test Positive Aware Network in…Read More

August 26, 2013, Washington, DC (reprinted from ACTF and NASTAD) The ACTF has a long history of working collaboratively with ViiV Healthcare to provide ADAPs access to discounted pricing on its HIV drugs. The special pricing of Tivicay, available to all state ADAPs, is in addition to…Read More

The Food and Drug Administration (FDA) announced August 12, 2013 that they approved a new integrase inhibitor against HIV, called dolutegravir (Tivicay). The drug works by keeping HIV from integrating into human DNA, which then prevents the virus from reproducing. The FDA approval is based upon the…Read More